{
  "id": 10390204,
  "title": "Innovent Biologics expands Phase 3 lung cancer trial globally",
  "url": "https://urgent.news/2026/09/28/innovent-biologics-expands-phase-3-lung-cancer-trial-globally",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T07:12:04.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/innovent-biologics-expands-phase-3-lung-cancer-trial-globally-161697.html"
  },
  "original_language": "en",
  "account": "Innovent Biologics has announced the expansion of its Phase 3 lung cancer trial, MarsLight-11, to include non-squamous non-small cell lung cancer (NSCLC) patients. The trial is assessing the investigational immunotherapy IBI363/TAK-928, a unique alpha-biased IL-2/PD-1 bispecific fusion protein co-developed by Innovent and Takeda. MarsLight-11 will now consist of two independent substudies, one focusing on squamous NSCLC and the other on non-squamous NSCLC. Each substudy will compare the efficacy and safety of IBI363 monotherapy against docetaxel in unresectable, locally advanced, or metastatic NSCLC patients who have progressed after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. IBI363/TAK-928 functions by simultaneously blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway, with the goal of reducing toxicity. The drug has received multiple designations, including Fast Track Designations from the U.S. FDA and Breakthrough Therapy Designations from China NMPA.",
  "summary": "Biopharmaceutical manufacturer Innovent Biologics expanded its global Phase 3 MarsLight 11 clinical trial of candidate IBI363 TAK 928 to evaluate patients with immunotherapy resistant non squamous non small cell lung cancer",
  "key_points": [
    "Innovent Biologics expands MarsLight-11 Phase 3 lung cancer trial globally.",
    "Trial now includes non-squamous non-small cell lung cancer patients.",
    "IBI363/TAK-928 bispecific fusion protein assessed against docetaxel."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}